The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Senior Director, Global Operations
Adlai Nortye USA Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
162 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centro de Investigacion Pergamino Sa - Clinica Pergamino S.A.
Buenos Aires, Argentina
- Fundacion Cenit Para la Investigacion En Neurociencias
Buenos Aires, Argentina
- Instituto de Investigaciones Metabólicas (idim) // Instituto de Investigaciones Metabólicas S.A.
Ciudad Autonoma de Buenos Aire, Argentina
- Ionc Srl- Instituto Oncológico de Córdoba
Córdoba, Argentina
- Fundacion Cori Para la Investigacion Y Prevencion del Cáncer
La Rioja, Argentina
- Centro Para la Atencion Integral del Paciente Oncologico - Caipo
San Miguel de Tucumán, Argentina
- Princess Alexandra Hospital
Brisbane, Australia
- Universitair Ziekenhuis Gent Uz Gent
Ghent, Belgium
- Universitair Ziekenhuis Brussel
Jette, Belgium
- Clinique Chc Montlégia
Liège, Belgium
- Clinique Saint-Pierre Dottignies Cspo
Ottignies, Belgium
- Chum
Montreal, Canada
- Cancercare Manitoba
Winnipeg, Canada
- Beijing Tongren Hospital
Beijing, China
- the First Affiliated Hospital of Bengbu Medical College
Bengbu, China
- Hunan Cancer Hospital
Changsha, China
- Xiangya Hospital Central South University
Changsha, China
- Sichuan Cancer Hospital
Chengdu, China
- Affiliated Cancer Hospital of Chongqing University
Chongqing, China
- the First Affiliated Hospital of Cqmu
Chongqing, China
- Affiliated Cancer Hospital of Guangzhou Medical University
Guangzhou, China
- Sun Yat-Sen University Cancer Center
Guangzhou, China
- Zhejiang Cancer Hospital
Hangzhou, China
- Anhui Provincial Cancer Hospital
Hefei, China
- Shandong Provincial Tumor Hospital
Jinan, China
- Yunnan Cancer Hospital
Kunming, China
- Cancer Hospital Affiliated To Guangxi Medical University
Naning, China
- Shanghai Dongfang Hospital
Shanghai, China
- Tianjin Cancer Hospital
Tianjin, China
- Henan Cancer Hospital
Zhengzhou, China
- the Fifth Affiliated Hospital of Sun Yat-Sen University
Zhuhai, China
- Centre Hospitalier Universitaire de Bordeaux
Bordeaux, France
- Centre Franois Baclesse
Caen, France
- Centre Leon Berard
Lyon, France
- Hopital de la Timone
Marseille, France
- Institut Regional Du Cancer de Montpellier
Montpellier, France
- Lhopital Prive Du Confluent Nantes
Nantes, France
- Clinique Hartmann
Neuilly-sur-Seine, France
- Hopital la Pitie Salpetriere
Paris, France
- Hopital Tenon
Paris, France
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 12 Dec 2020
- Primary completion
- 2 Nov 2025
- Completion
- 2 Nov 2025
- Last update posted
- 17 Nov 2025
- Registered enrollment
- 487
- Registry id
- NCT04338399
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.